Prospects for new restorative and neuroprotective treatments in Parkinson's disease

The degeneration of forebrain dopamine systems in Parkinson's disease has been an effective target for pharmaceutical research over the past four decades. However, although dopamine replacement may alleviate the symptoms of the disease, it does not halt the underlying neuronal degeneration. The...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 399; no. Supplementary; pp. A32 - A39
Main Authors Dunnett, Stephen B, Björklund, Anders
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 24.06.1999
Subjects
Animals
Antiparkinson Agents - therapeutic use
Cell Death
Gene Transfer Techniques
Humans
Levodopa - therapeutic use
Mutation
Nerve Degeneration
Neurology
Neurons - physiology
Neuroprotective Agents - therapeutic use
Parkinson Disease - genetics
Parkinson Disease - physiopathology
Parkinson Disease - surgery
Parkinson Disease - therapy
Parkinson's disease
Substantia Nigra - pathology
Online AccessGet full text

Cover

More Information
Summary:The degeneration of forebrain dopamine systems in Parkinson's disease has been an effective target for pharmaceutical research over the past four decades. However, although dopamine replacement may alleviate the symptoms of the disease, it does not halt the underlying neuronal degeneration. The past decade has seen major advances in identifying discrete genetic and molecular causes of parkinsonism and mapping the events involved in nigral cell death. This new understanding of the pathogenesis of the disease now offers novel prospects for therapy based on targeted neuroprotection of vulnerable neurons and effective strategies for their replacement.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0028-0836
1476-4687
DOI:10.1038/399a032